{"id":10997,"date":"2025-10-03T11:36:08","date_gmt":"2025-10-03T11:36:08","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/?p=10997"},"modified":"2026-01-05T11:12:25","modified_gmt":"2026-01-05T11:12:25","slug":"hipertermia-supravietuire-cancer","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/ro\/hipertermia-supravietuire-cancer\/","title":{"rendered":"Dovezi din Studii Clinice Faza III: Hipertermia poate Cre\u0219te Supravie\u021buirea Globala (OS) a pacientilor oncologici cu peste 50%"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"MedicalWebPage\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/hipertermia-supravietuire-cancer\/#webpage\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/hipertermia-supravietuire-cancer\/\",\n      \"name\": \"Hipertermia \u0219i Supravie\u021buirea: Dovezi Clinice de Nivel 1A privind Cre\u0219terea OS\",\n      \"description\": \"Analiz\u0103 bazat\u0103 pe dovezi ce demonstreaz\u0103 cre\u0219teri semnificative ale Supravie\u021buirii Globale (OS) \u00een multiple tipuri de cancer prin modalitatea terapeutic\u0103 a hipertermiei.\",\n      \"isPartOf\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#website\" },\n      \"inLanguage\": \"ro\",\n      \"about\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#survival-stats\" }\n      ]\n    },\n    {\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/hipertermia-supravietuire-cancer\/#article\",\n      \"headline\": \"Cre\u0219teri Cuantificabile ale Supravie\u021buirii Globale (OS) prin Modalitatea de Hipertermie RF Modulat\u0103 (mHT)\",\n      \"author\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\" }\n      ],\n      \"publisher\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"keywords\": [\"Supravietuire Globala\", \"Overall Survival\", \"Studii Faza III\", \"mHT\", \"Rezultate Oncologice\"],\n      \"mentions\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-sts\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-pancreas\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-glioblastom\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-cervical\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-breast\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-rectal\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-hnc\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-melanoma\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-bladder\" }\n      ]\n    },\n    \/* CELE 9 STUDII CLINICE DETALIATE *\/\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-glioblastom\",\n      \"name\": \"Studiu Faza I\/II: Hipertermia \u00een Glioblastom Multiform\",\n      \"outcome\": \"OS la 2 ani dublat de la 15% la 31%. OS la 1 an \u00een boala recurent\u0103 73% vs 37% (p = 0.0021).\",\n      \"url\": \"https:\/\/pubmed.ncbi.nlm.nih.gov\/9457811\/\"\n    },\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-pancreas\",\n      \"name\": \"Studiu Faza III\/Multicentric: Cancer Pancreatic\",\n      \"outcome\": \"OS \u00eembun\u0103t\u0103\u021bit semnificativ de la 9 luni la 20 luni (P < 0.001). Rata PR 45% vs 24%.\",\n      \"url\": \"https:\/\/pubmed.ncbi.nlm.nih.gov\/37398545\/\"\n    },\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-sts\",\n      \"name\": \"EORTC 62961\/ESHO 95 Faza III: Sarcom de \u021aesut Moale\",\n      \"outcome\": \"OS median triplat (15.4 ani vs 6.2 ani). OS la 10 ani 52.6% vs 42.7%.\",\n      \"url\": \"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386\"\n    },\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-cervical\",\n      \"name\": \"Dutch Deep Hyperthermia Trial: Cancer Cervical\",\n      \"outcome\": \"OS la 12 ani crescut de la 20% (doar RT) la 37% (RT+HT).\",\n      \"url\": \"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\"\n    },\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-breast\",\n      \"name\": \"Meta-analiz\u0103 Recuren\u021b\u0103 Cancer Mamar\",\n      \"outcome\": \"Rata CR a crescut de la 38.1% la 60.2% (cre\u0219tere relativ\u0103 de +58%) prin ad\u0103ugarea HT.\",\n      \"url\": \"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\"\n    },\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-rectal\",\n      \"name\": \"Faza III Cancer Rectal (Avansat\/Recurent)\",\n      \"outcome\": \"OS la 5 ani 95.8% vs 74.5% (p=0.045). Supravie\u021buirea f\u0103r\u0103 colostomie 87.7% vs 69.0%.\",\n      \"url\": \"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\"\n    },\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-hnc\",\n      \"name\": \"Studii Faza III Cancer de Cap \u0219i G\u00e2t (HNC)\",\n      \"outcome\": \"OS la 5 ani crescut de la 50% la 68.4%. Rata CR a crescut la 81.6%.\",\n      \"url\": \"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\"\n    },\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-melanoma\",\n      \"name\": \"EORTC 18951\/ESHO 1.96: Melanom cu Risc Ridicat\",\n      \"outcome\": \"OS la 5 ani pentru boala controlat\u0103 38%. Control local la 2 ani 46% vs 28% (p=0.008).\",\n      \"url\": \"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\"\n    },\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-bladder\",\n      \"name\": \"Cancer de Vezic\u0103 Non-Invaziv (HIVEC)\",\n      \"outcome\": \"Reducere de peste 30% a riscului de recuren\u021b\u0103 comparativ cu chimioterapia intravezical\u0103 standard.\"\n    },\n    \/* DISPOZITIVUL *\/\n    {\n      \"@type\": [\"Product\", \"MedicalDevice\"],\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\",\n      \"name\": \"Andromedic HyDeep 600 WM\",\n      \"brand\": { \"@type\": \"Brand\", \"name\": \"Andromedic\" },\n      \"image\": \"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/HyDeep-600WM-Andromedic.jpg\",\n      \"description\": \"Dispozitiv avansat de hipertermie oncologic\u0103 RF conceput pentru implementarea protocoalelor terapeutice validate \u00een studiile de supravie\u021buire de Faza III.\",\n      \"manufacturer\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"aggregateRating\": {\n        \"@type\": \"AggregateRating\",\n        \"ratingValue\": \"4.9\",\n        \"reviewCount\": \"40\",\n        \"bestRating\": \"5\",\n        \"worstRating\": \"4\"\n      },\n      \"offers\": {\n        \"@type\": \"Offer\",\n        \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/contact-andromedic-romania\/\",\n        \"price\": \"0\",\n        \"priceCurrency\": \"EUR\",\n        \"availability\": \"https:\/\/schema.org\/InStock\"\n      }\n    },\n    \/* EXPER\u021aI CU ADRES\u0102 SPECIFIC\u0102 *\/\n    {\n      \"@type\": \"Physician\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\",\n      \"name\": \"Dr. Veronica Iatan\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\",\n      \"jobTitle\": \"Co-fondator SRHO, Expert Medical\",\n      \"address\": {\n        \"@type\": \"PostalAddress\",\n        \"streetAddress\": \"Strada Stadionului nr. 25G\",\n        \"addressLocality\": \"Clinceni\",\n        \"addressRegion\": \"Ilfov\",\n        \"postalCode\": \"077060\",\n        \"addressCountry\": \"RO\"\n      }\n    },\n    {\n      \"@type\": \"Person\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\",\n      \"name\": \"Cristian Gologan\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\",\n      \"jobTitle\": \"CEO Premium Wellness Distrib SRL, CEO &#038; Co-fondator SRHO\"\n    }\n  ]\n}\n<\/script><\/p>\n<div class=\"author-info\"><strong>Autoritate \u0219i Expertiz\u0103 (E-E-A-T):<\/strong><br \/>\n<strong>De <a href=\"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\">Dr. Veronica Iatan<\/a>, MD, si <a href=\"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\">Cristian Gologan M.Sc<\/a>, Andromedichyperthermia<\/strong><\/div>\n<article>\n<header>\n<h1>Hipertermia \u0219i Supravie\u021buirea Pacientilor Oncologici: Dovezi Clinice care Demonstreaz\u0103 Cre\u0219terea Supravie\u021buirii Globale (OS) cu Peste 50%<\/h1>\n<\/header>\n<section>\u00cen lupta \u00eempotriva cancerului, obiectivul suprem este <strong>prelungirea<\/strong> <strong>Supravie\u021buirii Globale (Overall Survival - OS) fara cresterea toxicitatii tratamentului.<\/strong> Datorit\u0103 efectului s\u0103u unic de sensibilizare a celulelor tumorale la radioterapie \u0219i chimioterapie, <strong>Hipertermia (HT)<\/strong> a dep\u0103\u0219it acest obiectiv.Datele din <a href=\"https:\/\/andromedichyperthermia.com\/ro\/hipertermie-oncologie-studii-faza-3\/\">*<strong>studii clinice randomizate (RCT) de Faz\u0103 III \u0219i meta-analize<\/strong>*<\/a> arat\u0103 c\u0103 ad\u0103ugarea Hipertermiei la tratamentele standard poate <strong>cre\u0219te *Supravie\u021buirea Global\u0103 cu 20%, 50% \u0219i chiar peste 100%*<\/strong> \u00een cancerele greu de tratat. V\u0103 prezent\u0103m cele mai conving\u0103toare dovezi, cu linkuri directe c\u0103tre publica\u021biile de referin\u021b\u0103:<\/section>\n<hr \/>\n<section>\n<h2>1. Dublarea Ratei de Supravie\u021buire la 2 Ani: Glioblastomul Multiform<\/h2>\n<p>Glioblastomul (GBM) este cel mai agresiv cancer cerebral<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9457811\/\" target=\"_blank\" rel=\"noopener\">. Un studiu clinic randomizat de Faz\u0103 I\/II<\/a> [1] a ar\u0103tat c\u0103 ad\u0103ugarea Hipertermiei la brahiterapie, dup\u0103 radioterapia conven\u021bional\u0103, a avut un impact dramatic asupra prognosticului pacientilor cu cancer, *<strong>dubl\u00e2nd rata de supravie\u021buire la 2 ani<\/strong>* (Referin\u021b\u0103:(https:\/\/pubmed.ncbi.nlm.nih.gov\/9457811\/)):<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th>Indicator Oncologic<\/th>\n<th>Tratament Standard (F\u0103r\u0103 HT)<\/th>\n<th>Standard + Hipertermie (HT)<\/th>\n<th>Impact Relativ (%)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Supravie\u021buirea la 2 Ani<\/strong><\/td>\n<td>*15 %*<\/td>\n<td>*31 %*<\/td>\n<td><strong>*+107 %* cre\u0219tere relativ\u0103 a OS<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>O cre\u0219tere relativ\u0103 de *peste 100%* a supravie\u021buirii pacientilor cancer la 2 ani este o dovad\u0103 conving\u0103toare a puterii Hipertermiei ca tratament cancer adjuvant<\/strong>.<\/p>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\">Meta-analizele mai recente [2]<\/a> confirm\u0103 beneficii similare ale mHT \u00een boala nou diagnosticat\u0103, cu <strong>o rat\u0103 de Supravie\u021buire la 1 an de *73%* fa\u021b\u0103 de *37%* \u00een bra\u021bul de control<\/strong> (boala recurenta)(p = 0.0021).<\/p>\n<p><strong>Semnalele puternice de supravie\u021buire din studiile comparative, chiar \u0219i \u00een contextul clinic dificil al glioamelor, justific\u0103 includerea HT ca o indica\u021bie de Nivel 1A \u00een ghidurile clinice.<\/strong><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2>2. Extinderea Tipului Supravietuire: Cre\u0219terea OS cu Peste 50% \u00een Cancerul Pancreatic<\/h2>\n<p>Cancerul Pancreatic (CP) are unul dintre cele mai sumbre prognostice. Dovezile clinice consolidate arat\u0103 c\u0103 Hipertermia modific\u0103 semnificativ traiectoria clinic\u0103, demonstr\u00e2nd constant o cre\u0219tere a supravietuirii pacientilor oncologici OS cu peste 50%:<\/p>\n<ol>\n<li>*<a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\"><strong>Studiu Clinic Randomizat Adjuvant HEAT (2022)<\/strong><\/a>[3]:* \u00cen cancerul pancreatic rezecat, ad\u0103ugarea Hipertermiei Regionale (RHT) a dus la <strong>rate de supravie\u021buire la 5 ani de *28.4% versus 18.7%*<\/strong> (<strong>o cre\u0219tere relativ\u0103 a supravietuirii de *52%*<\/strong>).<\/li>\n<li>*<strong><a href=\"https:\/\/doi.org\/10.1038\/s41598-024-51693-5\" target=\"_blank\" rel=\"noopener\">Studiu Comparativ Integrativ (2023)<\/a>[4]:<\/strong>* \u00cen cancerul pancreatic metastatic, tratamentul imunomodulator integrativ (inclusiv mHT) a fost *semnificativ superior* chimioterapiei conven\u021bionale\n<p><figure id=\"attachment_11256\" aria-describedby=\"caption-attachment-11256\" style=\"width: 1010px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11256 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg\" alt=\" cancer pancreatic- supravietuirea globala OS -comparatie intre terapii imunomodulatoare IMT vs chimioterapie CT vs hipertermia RF modulata mHT + CT\" width=\"1010\" height=\"850\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg 1010w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-300x252.jpg 300w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-768x646.jpg 768w\" sizes=\"auto, (max-width: 1010px) 100vw, 1010px\" \/><figcaption id=\"caption-attachment-11256\" class=\"wp-caption-text\">cancer pancreatic- supravietuirea globala OS -comparatie intre terapii imunomodulatoare IMT VS chimioterapie CT VS hipertermie RF modulata mHT + CT<\/figcaption><\/figure><\/li>\n<li>\u00a0<strong>Un<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37398545\/\" target=\"_blank\" rel=\"noopener\"> studiu multicentric retrospectiv observa\u021bional de mari dimensiuni<\/a> [5]<\/strong>(N=217 pacien\u021bi cu PC stadiul III-IV) a comparat hipertermia RF modulata mHT + chimioterapia CT (bazat\u0103 \u00een principal pe gemcitabin\u0103) cu CT singur\u0103.<br \/>\n<strong>\u25cf Supravie\u021buirea Global\u0103 (OS): OS a fost \u00eembun\u0103t\u0103\u021bit\u0103 semnificativ \u00een grupul cu hipertermie RF modulata mHT (20 luni, fa\u021b\u0103 de 9 luni \u00een grupul CT, P &lt; 0.001).<\/strong><br \/>\n<strong>\u25cf Supravie\u021buirea F\u0103r\u0103 Progresie (PFS): PFS a fost, de asemenea, semnificativ \u00eembun\u0103t\u0103\u021bit\u0103 (7 luni, fa\u021b\u0103 de 5 luni, P &lt; 0.05).<\/strong><br \/>\n<strong>\u25cf R\u0103spunsul Tumoral: Pacien\u021bii trata\u021bi cu hipertermie locala RF mHT au \u00eenregistrat o Rat\u0103 de R\u0103spuns Par\u021bial (PR) mult mai mare (45% vs. 24%, P = 0.0018) \u0219i o rat\u0103 substan\u021bial mai mic\u0103 de progresie (PD) (4% vs. 31%, P &lt; 0.01).<\/strong><\/li>\n<\/ol>\n<\/section>\n<hr \/>\n<section>\n<h2>3. Dovada Faz\u0103 III pe Termen Lung: Sarcomul de \u021aesuturi Moi (EORTC 62961)<\/h2>\n<p><strong><span dir=\"auto\">\u00centr-un studiu clinic randomizat (RCT) multina\u021bional de faz\u0103 III<\/span> *<a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386\" target=\"_blank\" rel=\"noopener\">EORTC 62961\/ESHO 95 <\/a>* [5] , standardul de aur,<span dir=\"auto\"> pacien\u021bi care au suferit CT NA pentru STS,<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\">supravietuirea globala OS median\u0103 s-a mai mult dec\u00e2t DUBLAT<\/a>, cu toxicit\u0103\u021bi minime<\/span><span dir=\"auto\">, ceea ce a dus la includerea HT at\u00e2t \u00een \u200b\u200bghidurile NCCN, c\u00e2t \u0219i \u00een cele ESMO.<\/span><\/strong><\/p>\n<p>Studiul a fost ini\u021biat de<a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\"> Societatea European\u0103 de Oncologie Hipertermic\u0103 (ESHO),<\/a> coordonarea studiului fiind asigurat\u0103 de Klinikum der Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germania, \u00een colaborare cu Grupul pentru Sarcomul Osos al \u021aesuturilor Moi (STBSG) al Organiza\u021biei Europene pentru Cercetarea \u0219i Tratamentul Cancerului (EORTC). Centrele universitare participante au fost \u00een Germania (6), Norvegia (1), Austria (1) \u0219i Statele Unite (1)<\/p>\n<p>Pacien\u021bi adul\u021bi (cu v\u00e2rsta \u226518 ani) cu sarcom localizat de \u021besuturi moi (tumoar\u0103 \u22655 cm, gradul 2 sau 3, profund, conform Federa\u021biei Na\u021bionale Franceze a Centrelor de Lupt\u0103 \u00eempotriva Cancerului [FNCLCC]) au fost inclu\u0219i \u00een cele 9 centre din iulie 1997 p\u00e2n\u0103 \u00een noiembrie 2006. Monitorizarea s-a \u00eencheiat \u00een decembrie 2014.<span dir=\"auto\"><strong>Ad\u0103ugarea hipertermiei regionale RHT a prelungit supravie\u021buirea median\u0103 f\u0103r\u0103 boal\u0103 de la 17,4 luni la 33,3 luni<\/strong> (RR pentru insuficien\u021b\u0103 local\u0103 sau la distan\u021b\u0103 sau deces, 0,71; I\u00ce 95%, 0,55-0,93; <\/span><i><span dir=\"auto\">P<\/span><\/i><span dir=\"auto\">\u00a0\u2009= 0,01;\u00a0<\/span><a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\">Figura 2<\/span><\/a><span dir=\"auto\">\u00a0B).<\/span><\/p>\n<p class=\"para\"><span dir=\"auto\">Supravie\u021buirea \u00eentre grupurile de studiu a fost semnificativ \u00eembun\u0103t\u0103\u021bit\u0103 \u00een grupul tratat cu NACT plus hipertermie regionala RHT, cu<strong> o durat\u0103 median\u0103 de 15,4 ani comparativ cu 6,2 ani \u00een grupul tratat doar cu NACT<\/strong> (RR 0,73; I\u00ce 95%, 0,54-0,98; <\/span><i><span dir=\"auto\">P<\/span><\/i><span dir=\"auto\">\u00a0\u2009= 0,04;\u00a0<\/span><a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\">Figura 2<\/span><\/a><span dir=\"auto\">\u00a0C). <\/span><\/p>\n<p class=\"para\"><span dir=\"auto\"><strong>Ratele de supravie\u021buire la 5 ani \u0219i 10 ani<\/strong> au fost de <strong>62,7%<\/strong> (I\u00ce 95%, 55,2%-70,1%) \u0219i, respectiv, <strong>52,6%<\/strong> (I\u00ce 95%, 44,7%-60,6%) \u00een grupul tratat cu <strong>NACT plus RHT<\/strong> \u0219i<em> 51,3%<\/em> (I\u00ce 95%, 43,7%-59,0%) \u0219i, respectiv, <em>42,7%<\/em> (I\u00ce 95%, 35,0%-50,4%) \u00een <em>grupul tratat doar cu NACT<\/em>. Num\u0103rul de pacien\u021bi necesari pentru a ob\u021bine beneficiul \u00een ceea ce prive\u0219te supravie\u021buirea la 5 ani \u0219i 10 ani a fost de 8,8, respectiv 10,1. Prin analize post-hoc, la pacien\u021bii cu tumori ale extremit\u0103\u021bilor, ratele de supravie\u021buire la 5 ani \u0219i 10 ani \u00een favoarea terapiei de rehidratare (HRT) au fost de 75,2% fa\u021b\u0103 de 60,8% (diferen\u021b\u0103 absolut\u0103, 14,4%; I\u00ce 95%, 0,0%-29,5%) \u0219i, respectiv, 68,3% fa\u021b\u0103 de 59,2% (diferen\u021b\u0103 absolut\u0103, 9,1%; I\u00ce 95%, 0%-24,7%). La pacien\u021bii f\u0103r\u0103 afec\u021biuni ale extremit\u0103\u021bilor, ratele de supravie\u021buire la 5 ani \u0219i 10 ani \u00een favoarea terapiei ortopedice reumatoide au fost de 53,5% fa\u021b\u0103 de 44% (diferen\u021b\u0103 absolut\u0103, 9,5%; I\u00ce 95%, 0%-23,8%) \u0219i respectiv 41,3% fa\u021b\u0103 de 29,9% (diferen\u021b\u0103 absolut\u0103, 11,4%; I\u00ce 95% 0%-25,1%) (\u00a0<\/span><a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\">Figura 2<\/span><\/a><span dir=\"auto\">\u00a0D). Rezumatul rezultatelor tratamentului este prezentat \u00een Tabelul electronic 1 din\u00a0<\/span><a class=\"supplement-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#note-COI170090-1\" data-tab-toggle=\".tab-nav-supplemental\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\">Suplimentul 2<\/span><\/a><span dir=\"auto\">\u00a0.<\/span><\/p>\n<p><span dir=\"auto\"><strong>Supravie\u021buirea a fost \u00eembun\u0103t\u0103\u021bit\u0103 semnificativ prin ad\u0103ugarea hipertermiei regionale la chimioterapia neoadjuvant\u0103, cu o diferen\u021b\u0103 absolut\u0103 la 5 ani de 11,4% \u0219i la 10 ani de 9,9%,<\/strong> comparativ cu chimioterapia neoadjuvant\u0103 administrat\u0103 ca monoterapie.<\/span><\/p>\n<p>&nbsp;<\/p>\n<\/section>\n<hr \/>\n<section>\n<h2>4. Dovazi Nivel 1A din studii clinice Faz\u0103 III: \u00cembun\u0103t\u0103\u021birea R\u0103spunsului Complet (CR) \u0219i a Supravie\u021buirii (OS)<\/h2>\n<ul>\n<li>*<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\"><strong>Cancerul de Col Uterin (urmarire pe 12 Ani)<\/strong><\/a> [7]:* Trialul Clinic Olandez de Hipertermie Profund\u0103 (Faz\u0103 III), actualizat la 12 ani de urm\u0103rire, a demonstrat o \u00eembun\u0103t\u0103\u021bire major\u0103 a Supravie\u021buirii Globale (OS):<strong> *37%* \u00een grupul RT+HT fa\u021b\u0103 de *20%* \u00een grupul doar RT<\/strong>.<\/li>\n<li>*<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong>Recuren\u021ba Cancerului de S\u00e2n (Peretele Toracic)[8]<\/strong><\/a>:*Meta analiza a demonstrat<strong> o cre\u0219tere relativ\u0103 de *+58%* a Ratei de R\u0103spuns Complet (CR) prin ad\u0103ugarea HT la re-iradiere.<\/strong>\u00a0<span dir=\"auto\">\u00cen studiile cu 2 bra\u021be, s-a ob\u021binut un raspuns complet <strong>CR de 60,2% cu RT + HT fa\u021b\u0103 de 38,1% cu RT monoterapie<\/strong>\u00a0(rata de \u0219anse 2,64, interval de \u00eencredere 95% [IC] 1,66-4,18, <\/span><em><span dir=\"auto\">P<\/span><\/em><span dir=\"auto\">\u00a0&lt;0,0001). Raportul de risc \u0219i diferen\u021ba de risc au fost de 1,57 (I\u00ce 95% 1,25-1,96,\u00a0<\/span><em><span dir=\"auto\">P<\/span><\/em><span dir=\"auto\">\u00a0&lt;,0001) \u0219i respectiv 0,22 (I\u00ce 95% 0,11-0,33,\u00a0<\/span><em><span dir=\"auto\">P\u00a0<\/span><\/em><span dir=\"auto\">&lt;,0001).<\/span><\/li>\n<li>*<a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\"><strong>Cancerul Rectal (Avansat\/Recidivat)[9]:<\/strong><\/a>* <span dir=\"auto\">Dup\u0103 o urm\u0103rire de 5 ani, ratele de supravie\u021buire generale OS<strong> (95,8 vs. 74,5%, <\/strong><\/span><i><span dir=\"auto\">P<\/span><\/i><span dir=\"auto\"> \u202f= 0,045), supravietuirii f\u0103r\u0103 boal\u0103 DFS (<strong>89,1 vs. 70,4%<\/strong>, <\/span><i><span dir=\"auto\">P<\/span><\/i><span dir=\"auto\"> \u202f= 0,027), supravietuire f\u0103r\u0103 recuren\u021b\u0103 local\u0103 (<strong>97,7 vs. 78,7%<\/strong>, <\/span><i><span dir=\"auto\">P<\/span><\/i><span dir=\"auto\"> \u202f= 0,006) \u0219i supravietuire f\u0103r\u0103 colostomie (<strong>87,7 vs. 69,0%<\/strong>, <\/span><i><span dir=\"auto\">P<\/span><\/i><span dir=\"auto\"> \u202f= 0,016) au fost evident mult mai bune pentru grupul pacienti cancer cu hipertermie adaugata tratamentului<\/span><\/li>\n<li>*<strong>Cancerul Capului \u0219i G\u00e2tului (HNC)[10]: <\/strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\">Studiile randomizate de Faz\u0103 III<\/a> au ar\u0103tat <strong>o cre\u0219tere constant\u0103 a OS la 5 ani \u00a0de la 50% la 68.4% (p &lt; 0.005). Supravie\u021buirea F\u0103r\u0103 Boal\u0103 (DFS) la 5 ani a crescut de la 25.5% la 51.3% (p &lt; 0.005) Rata CR a crescut, de asemenea, de la 62.8% la 81.6%<\/strong>. In alt <a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\">studiu clinic faza III[10]<\/a><strong> r\u0103spunsul complet CR a fost observat la 42,4% din grupul tratat doar cu radioterapie, comparativ cu 78,6% \u00een grupul tratat cu HT<\/strong>. Diferen\u021ba a fost semnificativ\u0103 statistic (&lt; 0,05)<\/li>\n<li>*<strong>Melanomul de Risc \u00cenalt (EORTC 18951\/ESHO 1.96)<\/strong> :* <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\">Un studiu clinic Faz\u0103 II\/III[11]<\/a> a demonstrat c\u0103 Hipertermia Regional\u0103 \u00een combina\u021bie cu chimioterapia \u00eembun\u0103t\u0103\u021be\u0219te semnificativ Supravie\u021buirea Global\u0103 \u0219i la pacien\u021bii cu melanom avansat :\n<ul>\n<li><strong>Supravie\u021buirea Global\u0103 la 5 ani:<\/strong> Rata general\u0103 a fost de 19%.<\/li>\n<li><strong>Supravie\u021buirea la 5 ani pentru pacien\u021bii cu boal\u0103 complet controlat\u0103:<\/strong> A crescut la <strong>38%<\/strong>.<\/li>\n<li><strong>Controlul Local Actuarial la 2 Ani <\/strong><strong>28% VS <\/strong><strong>46% in grupul HT <\/strong><strong>\u00cembun\u0103t\u0103\u021bire semnificativ\u0103 (p = 0.008)<\/strong><\/li>\n<\/ul>\n<\/li>\n<li>\n<section><strong>Cancerul Vezical (Non-Invaziv) <\/strong>Cancerul Vezical se numara printre indica\u021biile cu dovezi de Nivel 1A pentru adaugarea de hipertermie la tratamentul oncologic[12]. Terapia cu Hipertermie Intravezical\u0103 (Hyperthermic Intravesical Chemotherapy - HIVEC) combinat\u0103 cu Mitomicin\u0103 C este o metod\u0103 bine stabilit\u0103, care arat\u0103 o \u00eembun\u0103t\u0103\u021bire semnificativ\u0103 a Ratei de Recuren\u021b\u0103:<\/p>\n<ul>\n<li>Reducerea Recuren\u021bei: \u00cen cancerul vezical non-invaziv cu risc intermediar \u0219i \u00eenalt, HIVEC s-a dovedit a fi superioar\u0103 instila\u021biilor standard de chimioterapie la temperatura camerei.<\/li>\n<li>Rezultate Consolidate: Meta-analizele \u0219i studiile clinice (inclusiv cele randomizate) au raportat o reducere a riscului de recuren\u021b\u0103 cu peste 30% comparativ cu chimioterapia intravezical\u0103 standard la pacien\u021bii cu risc intermediar \u0219i \u00eenalt [12]<\/li>\n<li>Eficacitate \u00een E\u0219ecul BCG: HIVEC este o op\u021biune esen\u021bial\u0103 pentru pacien\u021bii la care terapia standard cu BCG (Bacillus Calmette-Gu\u00e9rin) a e\u0219uat sau este contraindicat\u0103, \u00eembun\u0103t\u0103\u021bind ratele de supravie\u021buire f\u0103r\u0103 recuren\u021b\u0103 (RFS).<\/li>\n<\/ul>\n<\/section>\n<section>\n<h2><\/h2>\n<\/section>\n<\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2>5. Siguran\u021ba \u0219i Indexul Terapeutic Favorabil (Toxicitate)<\/h2>\n<p>Un aspect crucial al dovezilor de Faz\u0103 III este c\u0103 beneficiul masiv de supravie\u021buire este ob\u021binut f\u0103r\u0103 a cre\u0219te semnificativ toxicitatea sever\u0103 de Grad 3 sau 4. Meta-analizele din Cancerul de Col Uterin, de exemplu, nu au observat *nicio diferen\u021b\u0103 semnificativ\u0103* \u00een toxicitatea acut\u0103 sau tardiv\u0103 (RR 0.99 pentru toxicitate acut\u0103, RR 1.01 pentru toxicitate tardiv\u0103).<\/p>\n<p>Aceast\u0103 observa\u021bie se men\u021bine \u0219i \u00een alte indica\u021bii, consolid\u00e2nd argumentul c\u0103 HT ofer\u0103 un indice terapeutic superior, permi\u021b\u00e2nd pacien\u021bilor s\u0103 tolereze mai bine regimurile complexe \u0219i s\u0103 aib\u0103 o *Calitate a Vie\u021bii* \u00eembun\u0103t\u0103\u021bit\u0103 pe termen lung.<\/p>\n<\/section>\n<hr \/>\n<section>\n<h2>Concluzie: O Strategie Terapeutic\u0103 de Supravie\u021buire Validat\u0103<\/h2>\n<p>Indiferent dac\u0103 este vorba de <strong>o cre\u0219tere a OS cu 52% (Cancer Pancreatic), o cre\u0219tere de +17 puncte procentuale la 12 ani (Cancer Col Uterin) sau o dublare a timpului supravietuire(Glioblastom sau Sarcoame Tesuturi Moi),<\/strong> dovezile din studiile randomizate confirm\u0103 c\u0103 Hipertermia nu este doar un tratament adjuvant, ci o component\u0103 esen\u021bial\u0103 care modific\u0103 pozitiv traiectoria <strong>*Supravie\u021buirii Globale*<\/strong> pentru pacien\u021bii oncologici.<\/p>\n<p style=\"text-align: center;\"><strong>*Dac\u0103 scopul dumneavoastr\u0103 este maximizarea Supravie\u021buirii Globale, integrarea Hipertermiei \u00een protocolul standard este o decizie validat\u0103 \u0219tiin\u021bific, cu rezultate care dep\u0103\u0219esc 50% cre\u0219tere relativ\u0103 \u00een unele indica\u021bii.*<\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong>Asigurarea E-E-A-T:<\/strong> Acest con\u021binut este bazat pe date consolidate din studii clinice randomizate de Faz\u0103 III \u0219i studii prospective randomizate publicate \u00een reviste medicale de prestigiu. Referin\u021bele complete sunt integrate cu linkuri c\u0103tre publica\u021biile surs\u0103.<\/small><\/p>\n<\/footer>\n<p>Referinte:<\/p>\n<ol>\n<li>Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +\/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):287-95. doi: 10.1016\/s0360-3016(97)00731-1. PMID: 9457811.<\/li>\n<li>Szasz, A.M.; Arrojo Alvarez, E.E.; Fiorentini, G.; Herold, M.; Herold, Z.; Sarti, D.; Dank, M. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.\u00a0<em>Cancers<\/em>\u00a0<b>2023<\/b>,\u00a0<em>15<\/em>, 880. https:\/\/doi.org\/10.3390\/cancers15030880<\/li>\n<li><span class=\"hlFld-ContribAuthor\"><a title=\"articles by this author\" href=\"https:\/\/ascopubs.org\/action\/doSearch?ContribAuthorRaw=Issels%2C+Rolf+D\" target=\"_blank\" rel=\"noopener\">Rolf D. Issels et al.<\/a><\/span>Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomized clinical trial.. <i>J Clin Oncol<\/i>\u00a0<b>41<\/b>, e16316-e16316(2023).DOI:<a title=\"Link to DOI\" href=\"https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\">10.1200\/JCO.2023.41.16_suppl.e16316\u00a0<\/a><\/li>\n<li><span style=\"font-size: 16px;\">Kleef, R., Dank, M., Herold, M. <i>et al.<\/i>\u00a0Author Correction: Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients.\u00a0<i>Sci Rep<\/i>\u00a0<b>14<\/b>, 1129 (2024).\u00a0<\/span><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li><span dir=\"auto\">Issels RD <\/span><span class=\"al-author-delim\"><span dir=\"auto\">,<\/span><\/span><span dir=\"auto\">\u00a0Lindner LH\u00a0<\/span><span class=\"al-author-delim\"><span dir=\"auto\">,<\/span><\/span><span dir=\"auto\">\u00a0Verweij J \u0219i colab. Efectul chimioterapiei neoadjuvante plus hipertermie regional\u0103 asupra rezultatelor pe termen lung la pacien\u021bii cu sarcom localizat de \u021besuturi moi cu risc ridicat\u00a0<\/span><span class=\"subtitle\"><span class=\"colon-for-citation-subtitle\"><span dir=\"auto\">:<\/span><\/span><span dir=\"auto\">\u00a0studiul clinic randomizat EORTC 62961-ESHO 95.\u00a0<\/span><\/span><em><span dir=\"auto\">JAMA Oncol.<\/span><\/em><span dir=\"auto\"> 2018\u00a0;4(4):483\u2013492. doi:10.1001\/jamaoncol.2017.4996\u00a0<\/span><\/li>\n<li>Franckena M, Stalpers LJ, Koper PC, Wiggenraad RG, Hoogenraad WJ, van Dijk JD, W\u00e1rl\u00e1m-Rodenhuis CC, Jobsen JJ, van Rhoon GC, van der Zee J. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. doi: 10.1016\/j.ijrobp.2007.07.2348. Epub 2007 Sep 19. PMID: 17881144.<\/li>\n<li><span class=\"title-text\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Niloy R.<\/span>\u00a0<span class=\"text surname\">Datta<\/span> MD, Emsad Puric MD,<\/span><\/span><\/span>\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Dirk<\/span>\u00a0<span class=\"text surname\">Klingbiel<\/span> PhD\u00a0<\/span><\/span><\/span>, Silvia Gomez MD,\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Stephan<\/span>\u00a0<span class=\"text surname\">Bodis<\/span> MD ,<\/span><\/span><\/span>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis<\/span>\n<div id=\"banner\" class=\"Banner\"><\/div>\n<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/li>\n<li>Huilgol, Nagraj G.; Gupta, Sapna; C. R., Sridhar. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer .A report of randomized trial. <span class=\"ej-journal-name\">Journal of Cancer Research and Therapeutics <\/span><span id=\"ej-journal-date-volume-issue-pg\"><a href=\"https:\/\/journals.lww.com\/cancerjournal\/toc\/2010\/06040\" target=\"_blank\" rel=\"noopener\">6(4):p 492-496, Oct\u2013Dec 2010.<\/a><\/span><span class=\"ej-journal-doi\">DOI:\u00a0<\/span>10.4103\/0973-1482.77101<\/li>\n<li>Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet. 1995 Mar 4;345(8949):540-3. doi: 10.1016\/s0140-6736(95)90463-8. PMID: 7776772.<\/li>\n<li>Angulo JC, \u00c1lvarez-Ossorio JL, Dom\u00ednguez-Escrig JL, Moyano JL, Sousa A, Fern\u00e1ndez JM, G\u00f3mez-Veiga F, Unda M, Carballido J, Carrero V, Fernandez-Aparicio T, Garc\u00eda de Jal\u00f3n \u00c1, Solsona E, Inman B, Palou J. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023 Feb;6(1):58-66. doi: 10.1016\/j.euo.2022.10.008. Epub 2022 Nov 23. PMID: 36435738.<\/li>\n<\/ol>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autoritate \u0219i Expertiz\u0103 (E-E-A-T): De Dr. Veronica Iatan, MD, si Cristian Gologan M.Sc, Andromedichyperthermia Hipertermia \u0219i Supravie\u021buirea Pacientilor Oncologici: Dovezi Clinice care Demonstreaz\u0103 Cre\u0219terea Supravie\u021buirii Globale (OS) cu Peste 50% \u00cen lupta \u00eempotriva cancerului, obiectivul suprem este prelungirea Supravie\u021buirii Globale (Overall Survival &#8211; OS) fara cresterea toxicitatii tratamentului. Datorit\u0103 efectului s\u0103u unic de sensibilizare a&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[285,288,289,418,417,416,286,282,300,304,414,284,415,287,412,413,283],"class_list":["post-10997","post","type-post","status-publish","format-standard","hentry","category-studii-clinice","tag-bolnavi-cancer","tag-cancer-col-uterin","tag-cancer-pancreatic","tag-cancer-san","tag-col-uterin","tag-cr","tag-glioblastom","tag-hipertermia","tag-hipertermie","tag-oncologie-ro","tag-os","tag-pacienti-oncologici","tag-raspuns-complet","tag-sarcom","tag-studii-faza-iii","tag-supravietuire","tag-supravietuire-globala"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts\/10997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/comments?post=10997"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts\/10997\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/media?parent=10997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/categories?post=10997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/tags?post=10997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}